2013

1. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial

   European Urology, Vol. 63, Núm. 2, pp. 283-295

2. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: A post hoc analysis of a randomized European-Australian Phase 3 trial

   BMC Urology, Vol. 13

3. Mirabegron for the treatment of overactive bladder: A prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

   International Journal of Clinical Practice, Vol. 67, Núm. 7, pp. 619-632